Seqens Seqens

X

Find Radio Compass News for Flurandrenolone

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES

0

left grey arrow
right gray arrow
  • LOTION;TOPICAL - 0.05%
  • TAPE;TOPICAL - 0.004MG/SQ CM

https://www.prnewswire.com/news-releases/almirall-acquires-allergan-us-medical-dermatology-portfolio-300716808.html

PR NEWSWIRE
21 Sep 2018

http://www.pharmatimes.com/news/almirall_acquires_allergans_us_dermatology_portfolio_for_$650_million_1246917

G Underwood PHARMA TIMES
03 Aug 2018

http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205343

FDA
22 Dec 2016

https://www.pharmacompass.com/pdf/news/teligent-pharmas-generic-flurandrenolide-approved-in-us-to-treat-inflammation-1460799704.pdf

FDA
13 Apr 2016

http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/01/report-card-fda-gets-a-solid-b-on-timely-responding-to-section-505w-discontinuation-citizen-petition.html

Kurt R. Karst FDA LAW BLOG
25 Jan 2015
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY